

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

YH-13

RRID:CVCL_1795

Type: Cell Line

Proper Citation

RRID:CVCL_1795

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1795

Proper Citation: RRID:CVCL_1795

Description: Cell line YH-13 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:7947440](#), [PMID:8145054](#), [PMID:16232199](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: YH-13

Synonyms: YH13, YH

Cross References: CLO:CLO_0009906, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1043, BioSample:SAMN03472800, BioSample:SAMN10987935, cancercellines:CVCL_1795, Cell_Model_Passport:SIDM00316, CGH-DB:158-1, ChEMBL-Cells:ChEMBL3308223, ChEMBL-Targets:ChEMBL2366164, Cosmic:687591, Cosmic:909905, Cosmic:2367556, Cosmic-CLP:909905, DepMap:ACH-000469, EGA:EGAS00001000978, GDSC:909905, GEO:GSM887747, GEO:GSM888842, GEO:GSM1670585, IARC_TP53:27268, JCRB:IFO50493, LiGeA:CCLE_419, LINCS_LDP:LCL-1392,

PharmacDB:YH13_1684_2019, PRIDE:PXD030304, Progenetix:CVCL_1795, PubChem_Cell_line:CVCL_1795, Wikidata:Q54995420

ID: CVCL_1795

Record Creation Time: 20220427T221739+0000

Record Last Update: 20260913T010458+0000

Ratings and Alerts

No rating or validation information has been found for YH-13.

No alerts have been found for YH-13.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell reports, 42(12), 113503.